샘플 요청 목록

 카트 문의
시장보고서
상품코드
1542651

세계의 POC(Point-of-Care)/신속 진단 시장

Point-of-Care/Rapid Diagnostics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 POC(Point-of-Care)/신속 진단 시장은 2030년까지 464억 달러에 도달

2023년에 277억 달러로 추정된 세계의 POC(Point-of-Care)/신속 진단 시장은 2023-2030년의 분석 기간에 CAGR 7.7%로 성장하며, 2030년에는 464억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 기타 POC 제품은 CAGR 6.1%를 기록하며, 분석 기간 종료시에는 33억 달러에 달할 것으로 예측됩니다. 남용 약물 검사 제품 부문의 성장률은 분석 기간 중 CAGR 6.4%로 추정됩니다.

미국 시장은 75억 달러로 추정, 중국은 CAGR 11.2%로 성장 예측

미국의 POC(Point-of-Care)/신속 진단 시장은 2023년에 75억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 100억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 11.2%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 5.3%와 5.9%로 예측됩니다. 유럽에서는 독일이 CAGR 5.9%로 성장할 것으로 예측됩니다.

세계의 POC(Point-of-Care)/신속 진단 시장 - 주요 동향과 촉진요인 정리

헬스케어에 혁명을 초래하는 POC(Point-of-Care)/신속 진단 영향

POC(Point-of-Care) 또는 신속 진단은 환자의 진료 현장 또는 그 근처에서 수행되는 의료 검사로, 대규모 검사 인프라 없이도 즉각적인 결과를 얻을 수 있습니다. POC 진단은 일반적으로 휴대용 기기나 검사 키트를 이용한 간단한 절차가 필요하며, 최소한의 교육만 받으면 작동할 수 있는 간단한 절차가 필요하며, 감염 탐지, 혈당 모니터링, 심장 마커, 임신 검사 등 다양한 용도를 포함합니다. 예를 들어 가정용 임신 테스트 및 COVID-19 항원 검사에 일반적으로 사용되는 측면 흐름 분석은 검체에서 특정 바이오마커의 존재를 감지하여 신속하게 시각적 결과를 얻을 수 있습니다. 휴대용 혈액 분석기 및 휴대용 분자 검사 장비와 같은 다른 POC 기술은 미세 유체 공학 및 핵산 증폭과 같은 첨단 기술을 사용하여 정확하고 시기적절한 결과를 제공하며, POC 진단의 핵심 장점은 의료 전문가에게 즉각적이고 실용적인 정보를 제공하여 보다 신속한 임상 결정을 내리고 환자의 예후를 개선할 수 있다는 것입니다.

POC/신속진단은 다양한 의료 현장에서 어떻게 활용되고 있는가?

POC 검사는 다양한 의료 현장에서 필수적인 요소로 의료 서비스의 효율성과 효과성을 높이고 있습니다. 응급실에서는 POC 검사를 통해 심근경색과 같은 질환을 신속하게 진단하여 생명을 구하는 데 필수적인 즉각적인 개입을 가능하게 합니다. 1차 진료 및 외래 진료소에서는 연쇄상구균 감염, 독감, 요로 감염과 같은 일반적인 질병을 현장에서 검사하고 진단할 수 있으며, 재진료의 필요성을 줄이고 환자 치료의 효율성을 높일 수 있습니다. 원격지나 지방의 의료시설은 첨단 검사 능력이 부족한 경우가 많으며, 의료 접근성의 격차를 해소하고 필수적인 의료 서비스를 제공하기 위해 POC 진단에 크게 의존하고 있습니다. 또한 POC 진단은 만성질환 관리에서 중요한 역할을 하고 있으며, 환자가 집에서 당뇨병이나 응고장애와 같은 증상을 모니터링할 수 있으며, 건강을 더 잘 관리할 수 있도록 도와주며, POC 진단은 다용도하고 신속하므로 다양한 의료 환경에서 필수적인 툴이 되고 있습니다. 필수적인 툴이 되고 있습니다.

POC/신속 진단 기술 동향은?

POC(Point-of-Care) 진단 분야는 기술 혁신과 효율적인 헬스케어 솔루션에 대한 수요 증가로 인해 급속한 발전을 거듭하고 있습니다. 중요한 동향 중 하나는 디지털 헬스 기술의 통합으로, POC 기기에는 검사 결과를 전자 의료 기록(EHR) 및 모바일 건강 용도에 직접 업로드할 수 있는 연결 기능이 탑재되어 실시간 데이터 공유 및 환자 원격 모니터링이 용이해집니다. 멀티플렉스 검사 플랫폼의 개발도 하나의 샘플에서 여러 바이오마커를 동시에 검출할 수 있는 멀티플렉스 검사 플랫폼의 개발도 하나의 동향 중 하나이며, 특히 중복 감염 진단 및 종합적인 건강 검진에 유용합니다. 마이크로플루이딕스공학 및 랩온칩 기술의 발전은 민감도와 특이성을 향상시킨 보다 작고 휴대 가능한 POC 장비의 개발로 이어지고 있습니다. 또한 인공지능(AI)과 머신러닝 알고리즘의 사용은 POC 진단의 정확도와 예측 능력을 향상시키고 환자 데이터에 기반한 개인화된 인사이트을 제공합니다. 이러한 추세는 신속 진단의 상황을 변화시키고 있으며, 보다 접근성이 높고 신뢰할 수 있으며 더 광범위한 의료 시스템에 통합되고 있습니다.

POC/신속 진단 시장의 성장을 가속하는 요인은 무엇일까?

POC/신속진단 시장의 성장은 적시에 정확한 진단 솔루션에 대한 수요 증가를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 당뇨병이나 COVID-19와 같은 만성질환 및 감염성 질환의 유병률 증가는 POC 진단을 통해 이러한 질환을 조기에 발견하고 관리할 수 있으므로 중요한 촉진제 역할을 하고 있습니다. 기술의 발전은 POC 기기의 기능과 사용 편의성을 향상시켜 다양한 의료 현장에서의 채택을 촉진하고 있습니다. 또한 맞춤형 의료에 대한 중요성이 강조되고 의료의 분산화는 POC 진단이 개인화된 치료 계획을 지원하고 전통적인 임상 환경 외의 치료를 촉진하므로 시장 성장을 가속하고 있습니다. 또한 의료 인프라에 대한 투자 증가와 원격의료 서비스 확대도 신속 진단 툴에 대한 수요를 증가시키고 있습니다. 원격지에서의 질병 감시와 의료 서비스 접근성을 향상시키기 위한 공중보건 노력은 시장 확대를 더욱 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 현장 진료/신속 진단 시장의 견고한 성장을 보장하고 있으며, 현대 의료 서비스 제공 및 질병 관리에서 현장 진료/신속 진단의 중요한 역할을 강조하고 있습니다.

조사 대상 기업의 예(총 13건)

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Becton, Dickinson and Company
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • Instrumentation Laboratory
  • Johnson & Johnson
  • Nova Biomedical Corporation
  • PTS Diagnostics
  • Quidel Corporation
  • Roche Diagnostics(Schweiz) AG
  • Sekisui Diagnostics LLC
  • Siemens AG
  • Trinity Biotech PLC

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.09.02

Global Point-of-Care/Rapid Diagnostics Market to Reach US$46.4 Billion by 2030

The global market for Point-of-Care/Rapid Diagnostics estimated at US$27.7 Billion in the year 2023, is expected to reach US$46.4 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Other POC Products, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Drugs-of-Abuse Testing Products segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.5 Billion While China is Forecast to Grow at 11.2% CAGR

The Point-of-Care/Rapid Diagnostics market in the U.S. is estimated at US$7.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$10.0 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Point-of-Care/Rapid Diagnostics Market - Key Trends and Drivers Summarized

Revolutionizing Healthcare: The Impact of Point-of-Care/Rapid Diagnostics

Point-of-care (POC) or rapid diagnostics are medical tests performed at or near the site of patient care, providing immediate results without the need for extensive laboratory infrastructure. These diagnostics cover a wide range of applications, including infectious disease detection, blood glucose monitoring, cardiac markers, and pregnancy testing. POC diagnostics typically involve simple procedures using portable devices or test kits that require minimal training to operate. For instance, lateral flow assays, commonly used in home pregnancy tests and COVID-19 antigen tests, allow for rapid visual results by detecting the presence of specific biomarkers in a sample. Other POC technologies, such as portable blood analyzers and handheld molecular testing devices, use advanced techniques like microfluidics and nucleic acid amplification to deliver precise and timely results. The core advantage of POC diagnostics is their ability to provide healthcare professionals with immediate, actionable information, facilitating faster clinical decisions and improving patient outcomes.

How Are Point-of-Care/Rapid Diagnostics Utilized in Various Medical Settings?

Point-of-care diagnostics are integral to various medical settings, enhancing the efficiency and effectiveness of healthcare delivery. In emergency departments, POC tests are used to quickly diagnose conditions like myocardial infarction, enabling immediate intervention that can be critical in saving lives. In primary care and outpatient clinics, these diagnostics allow for on-the-spot testing and diagnosis of common conditions such as strep throat, influenza, and urinary tract infections, reducing the need for follow-up visits and streamlining patient care. Remote and rural healthcare facilities, often lacking advanced laboratory capabilities, rely heavily on POC diagnostics to provide essential medical services, bridging the gap in healthcare access. Additionally, POC diagnostics play a crucial role in chronic disease management, allowing patients to monitor conditions such as diabetes and coagulation disorders at home, thereby maintaining better control over their health. The versatility and rapid turnaround of POC diagnostics make them indispensable tools across diverse healthcare environments.

What Are the Current Trends in Point-of-Care/Rapid Diagnostic Technology?

The field of point-of-care diagnostics is experiencing rapid advancements driven by technological innovations and the increasing demand for efficient healthcare solutions. One significant trend is the integration of digital health technologies, where POC devices are equipped with connectivity features to upload test results directly to electronic health records (EHRs) and mobile health applications, facilitating real-time data sharing and remote patient monitoring. The development of multiplex testing platforms is another trend, enabling the simultaneous detection of multiple biomarkers from a single sample, which is particularly useful for diagnosing co-infections or comprehensive health screenings. Advances in microfluidics and lab-on-a-chip technologies are leading to the creation of more compact and portable POC devices with enhanced sensitivity and specificity. Additionally, the use of artificial intelligence (AI) and machine learning algorithms is improving the accuracy and predictive capabilities of POC diagnostics, offering personalized insights based on patient data. These trends are revolutionizing the landscape of rapid diagnostics, making them more accessible, reliable, and integrated into the broader healthcare system.

What Factors Are Driving the Growth in the Point-of-Care/Rapid Diagnostics Market?

The growth in the point-of-care/rapid diagnostics market is driven by several factors, reflecting the increasing need for timely and accurate diagnostic solutions. The rising prevalence of chronic diseases and infectious diseases, such as diabetes and COVID-19, is a significant driver, as POC diagnostics enable early detection and management of these conditions. Technological advancements are enhancing the functionality and user-friendliness of POC devices, encouraging their adoption across various healthcare settings. The growing emphasis on personalized medicine and the shift towards decentralized healthcare are also propelling market growth, as POC diagnostics support individualized treatment plans and facilitate care outside traditional clinical environments. Additionally, increasing investments in healthcare infrastructure and the expansion of telemedicine services are boosting demand for rapid diagnostic tools. Public health initiatives aimed at improving disease surveillance and healthcare accessibility in remote areas further support market expansion. These factors collectively ensure robust growth in the point-of-care/rapid diagnostics market, underscoring their critical role in modern healthcare delivery and disease management.

Select Competitors (Total 13 Featured) -

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Becton, Dickinson and Company
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • Instrumentation Laboratory
  • Johnson & Johnson
  • Nova Biomedical Corporation
  • PTS Diagnostics
  • Quidel Corporation
  • Roche Diagnostics (Schweiz) AG
  • Sekisui Diagnostics LLC
  • Siemens AG
  • Trinity Biotech PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Point-Of-Care/Rapid Diagnostics: Overview & Outlook
    • Point-of-Care/Rapid Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emphasis on Decentralized Testing & Laboratory Strengthening Programs Augurs Well
    • Emergency Departments Rely on Rapid POC Diagnostics
    • Rapid POC Diagnostics Streamline Urgent Cardiac Care Settings
    • Rapid POC Diagnostics Gain Traction in Diagnosis of STD
    • Rapid POC Diagnostics for Tuberculosis Diagnosis
    • Quality Assurances Accelerate Adoption
    • Issues & Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Point-of-Care/Rapid Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Glucose Monitoring Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Glucose Monitoring Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Glucose Monitoring Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cardiometabolic Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cardiometabolic Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Cardiometabolic Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Infectious Disease Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Infectious Disease Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Infectious Disease Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Coagulation Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Coagulation Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Coagulation Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pregnancy & Fertility Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Pregnancy & Fertility Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Pregnancy & Fertility Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Tumor/Cancer Marker Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Tumor/Cancer Marker Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Tumor/Cancer Marker Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Urinalysis Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Urinalysis Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Urinalysis Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Cholesterol Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Cholesterol Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Cholesterol Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Hematology Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Hematology Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Hematology Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Drugs-of-Abuse Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Drugs-of-Abuse Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Drugs-of-Abuse Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Fecal Occult Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Fecal Occult Testing Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Fecal Occult Testing Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other POC Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other POC Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Other POC Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for OTC-based Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 41: World Historic Review for OTC-based Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 42: World 16-Year Perspective for OTC-based Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Prescription-based Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Prescription-based Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 45: World 16-Year Perspective for Prescription-based Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Lateral Flow Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Lateral Flow Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 48: World 16-Year Perspective for Lateral Flow Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 49: World Recent Past, Current & Future Analysis for Dipsticks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 50: World Historic Review for Dipsticks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 51: World 16-Year Perspective for Dipsticks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 52: World Recent Past, Current & Future Analysis for Microfluidics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: World Historic Review for Microfluidics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: World 16-Year Perspective for Microfluidics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 55: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 56: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 57: World 16-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 58: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 59: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 60: World 16-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 61: World Point-of-Care/Rapid Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 62: USA Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Canada 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • JAPAN
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Japan 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • CHINA
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: China 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: China 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • EUROPE
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Point-of-Care/Rapid Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • FRANCE
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: France 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: France 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: France 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • GERMANY
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: UK 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Spain 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Spain 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Russia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Russia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Europe Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Europe 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 188: Australia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Australia Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Australia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 191: Australia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Australia Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Australia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • INDIA
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 194: India Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: India 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 197: India Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: India Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: India 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 200: India Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: India Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: India 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 206: South Korea Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: South Korea Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: South Korea 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 209: South Korea Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: South Korea Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: South Korea 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 218: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Rest of Asia-Pacific Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 227: Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 230: Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 236: Argentina Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Argentina Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Argentina 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 239: Argentina Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Argentina Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Argentina 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 245: Brazil Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Brazil Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Brazil 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 248: Brazil Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Brazil Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Brazil 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 254: Mexico Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Mexico Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Mexico 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 257: Mexico Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Mexico Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Mexico 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 263: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Rest of Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Rest of Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 266: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Rest of Latin America Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Rest of Latin America 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 275: Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 278: Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 284: Iran Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Iran Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Iran 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 287: Iran Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Iran Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Iran 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 293: Israel Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Israel Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Israel 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 296: Israel Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Israel Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Israel 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 302: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Saudi Arabia Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Saudi Arabia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 305: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Saudi Arabia Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Saudi Arabia 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 311: UAE Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: UAE Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: UAE 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 314: UAE Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: UAE Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: UAE 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 320: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Rest of Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Rest of Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 323: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Rest of Middle East Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Rest of Middle East 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030
  • AFRICA
    • Point-of-Care/Rapid Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Point-of-Care/Rapid Diagnostics by Product - Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Product - Percentage Breakdown of Value Sales for Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products and Other POC Products for the Years 2014, 2024 & 2030
    • TABLE 329: Africa Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 330: Africa Historic Review for Point-of-Care/Rapid Diagnostics by Mode - OTC-based Testing and Prescription-based Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 331: Africa 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Mode - Percentage Breakdown of Value Sales for OTC-based Testing and Prescription-based Testing for the Years 2014, 2024 & 2030
    • TABLE 332: Africa Recent Past, Current & Future Analysis for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 333: Africa Historic Review for Point-of-Care/Rapid Diagnostics by Platform - Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 334: Africa 16-Year Perspective for Point-of-Care/Rapid Diagnostics by Platform - Percentage Breakdown of Value Sales for Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제